Skip to main content
logo
Grace Therapeutics, Inc. (GRCE)
NASDAQ: GRCE · Real-Time Price · USD
2.154
+0.024 (1.13%)
Aug 19, 2026, 12:13 PM EDT - Market open

Grace Therapeutics Financials Overview

Millions USD. Fiscal year is Apr - Mar.

Revenue & Profits
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Revenue
------
Revenue Growth
------
Gross Profit
------
Operating Income
-10.37-11.08-16.68-11.28-18.21-12.14
Net Income
-20.22-7.79-9.57-12.85-42.43-9.82
Earnings Per Share
-1.20-0.47-0.79-1.35-5.71-1.60
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cash & Investments
13.7616.9822.1323.0127.8943.66
Total Debt
----0.490.3
Net Cash (Debt)
13.7616.9822.1323.0127.4143.37
Net Cash Growth
-31.24%-23.30%-3.79%-16.05%-36.80%-28.49%
Net Cash Per Share
0.821.031.832.413.697.06

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Operating Cash Flow
-10.29-8.87-14.9-12.33-15.91-17.23
Capital Expenditures
----0.02-0.02-
Free Cash Flow
-10.29-8.87-14.9-12.36-15.93-17.23
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Gross Margin
------
Operating Margin
------
Profit Margin
------
FCF Margin
------

Valuation
Chart
Fiscal YearCurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingAug '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
PS Ratio
------